TrialSignal transduction and targeted therapy2026

Induction and concurrent aumolertinib with radiotherapy for EGFR-mutated stage III NSCLC: results of phase III ADVANCE trial and real-world validation.

Nan Bi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.